With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
REGN trades against a final fair-value range of $917.25-$1,505.07, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
In a severe downside scenario, Regeneron faces simultaneous shocks: Eylea loses material share to Vabysmo and biosimilars, Dupixent growth sharply decelerates, and pipeline failures force a structural reset in operating margins below 25%. Even under these dire conditions, baseline FCFFFree cash flow to firmCash flow available to all capital providers (debt and equity) before financing costs. Discounted at WACC to derive enterprise value. generation anchors intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. near $917, indicating the downside is already heavily priced in.
Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
Dupixent matures faster than expected and label expansions underperform, halting the company's primary top-line engine.
Elevated R&D spend of $5.8B yields zero meaningful commercial blockbusters, structurally degrading long-term ROIC and locking in compressed margins.
| Line item | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|---|
| Revenue | — | $12.17B | $13.12B+7.8% | $14.20B+8.2% | $14.34B+1.0% | +4.2% |
| Gross profit | — | $10.61B | $11.30B | $12.23B | $12.24B | +3.6% |
| Operating income | — | $4.74B | $4.05B | $3.99B | $3.70B | -6.0% |
| Net income | — | $4.34B | $3.95B-9.0% | $4.41B+11.6% | $4.50B+2.0% | +0.9% |
| EPS (diluted) | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | -12.9% |
| EBITDA | — | $5.26B | $4.69B | $5.32B | $5.82B | +2.6% |
| R&D | — | $3.85B | $4.63B | $5.23B | $5.85B | +11.0% |
| SG&A | — | $2.12B | $2.63B | $2.95B | $2.70B | +6.3% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Major clinical trial failures in late-stage oncology assets. | Monitor | Deterioration versus the report thesis |
| ROIC structurally breaks below the 10% threshold. | Monitor | Deterioration versus the report thesis |
